Partial responses in NSCLC were seen across a wide dose range (150–1000 mg day−1), and pharmacodynamic data showed that EGFR signalling was consistently inhibited in skin biopsies at all doses above 150 mg day−1 (Albanell et al, 2002). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.